0K16 logo

Evolus LSE:0K16 Stock Report

Last Price

US$14.92

Market Cap

US$901.6m

7D

-10.3%

1Y

86.5%

Updated

08 Nov, 2024

Data

Company Financials +

Evolus, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Evolus
Historical stock prices
Current Share PriceUS$14.92
52 Week HighUS$17.81
52 Week LowUS$7.92
Beta1.31
11 Month Change-10.74%
3 Month Change12.03%
1 Year Change86.51%
33 Year Change101.95%
5 Year Change4.69%
Change since IPO-24.81%

Recent News & Updates

Recent updates

Shareholder Returns

0K16GB PharmaceuticalsGB Market
7D-10.3%-8.9%0.4%
1Y86.5%-5.4%7.6%

Return vs Industry: 0K16 exceeded the UK Pharmaceuticals industry which returned -5.4% over the past year.

Return vs Market: 0K16 exceeded the UK Market which returned 7.6% over the past year.

Price Volatility

Is 0K16's price volatile compared to industry and market?
0K16 volatility
0K16 Average Weekly Movement8.8%
Pharmaceuticals Industry Average Movement6.5%
Market Average Movement4.7%
10% most volatile stocks in GB Market9.9%
10% least volatile stocks in GB Market2.5%

Stable Share Price: 0K16's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0K16's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
2012304David Moatazediwww.evolus.com

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names.

Evolus, Inc. Fundamentals Summary

How do Evolus's earnings and revenue compare to its market cap?
0K16 fundamental statistics
Market capUS$901.62m
Earnings (TTM)-US$55.46m
Revenue (TTM)US$248.33m

3.6x

P/S Ratio

-16.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0K16 income statement (TTM)
RevenueUS$248.33m
Cost of RevenueUS$74.64m
Gross ProfitUS$173.69m
Other ExpensesUS$229.15m
Earnings-US$55.46m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.88
Gross Margin69.94%
Net Profit Margin-22.33%
Debt/Equity Ratio2,057.9%

How did 0K16 perform over the long term?

See historical performance and comparison